These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 8398069)
21. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Chabot MC; Wykle RL; Modest EJ; Daniel LW Cancer Res; 1989 Aug; 49(16):4441-5. PubMed ID: 2743333 [TBL] [Abstract][Full Text] [Related]
22. ET-18-OCH3 inhibits nuclear factor-kappa B activation by 12-O-tetradecanoylphorbol-13-acetate but not by tumor necrosis factor-alpha or interleukin 1 alpha. Daniel LW; Civoli F; Rogers MA; Smitherman PK; Raju PA; Roederer M Cancer Res; 1995 Nov; 55(21):4844-9. PubMed ID: 7585518 [TBL] [Abstract][Full Text] [Related]
23. The antitumor ether lipid 1-Q-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1. Samadder P; Richards C; Bittman R; Bhullar RP; Arthur G Anticancer Res; 2003; 23(3B):2291-5. PubMed ID: 12894505 [TBL] [Abstract][Full Text] [Related]
24. Differentiation of HL-60 cells distinguishes between cytostatic and cytotoxic effects of the alkylphospholipid ET-18-OCH3. Civoli F; Pauig SB; Daniel LW Cancer Chemother Pharmacol; 1996; 38(3):269-72. PubMed ID: 8646802 [TBL] [Abstract][Full Text] [Related]
25. Growth inhibitory effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Peters AC; Ahmad I; Janoff AS; Pushkareva MY; Mayhew E Lipids; 1997 Oct; 32(10):1045-54. PubMed ID: 9358430 [TBL] [Abstract][Full Text] [Related]
26. Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Small GW; Strum JC; Daniel LW Lipids; 1997 Jul; 32(7):715-23. PubMed ID: 9252959 [TBL] [Abstract][Full Text] [Related]
27. 1-O-Octadecyl-2-O-methylglycerophosphocholine inhibits protein kinase C-dependent phosphorylation of endogenous proteins in MCF-7 cells. Zhou X; Arthur G Biochem J; 1997 Jun; 324 ( Pt 3)(Pt 3):897-902. PubMed ID: 9210414 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of Na+/H+ exchanger activity by an alkyl-lysophospholipid analogue in a human breast cancer cell line. Besson P; Goré J; Vincent E; Hoinard C; Bougnoux P Biochem Pharmacol; 1996 May; 51(9):1153-8. PubMed ID: 8645337 [TBL] [Abstract][Full Text] [Related]
29. Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system. Cabaner C; Gajate C; Macho A; Muñoz E; Modolell M; Mollinedo F Br J Pharmacol; 1999 Jun; 127(4):813-25. PubMed ID: 10433487 [TBL] [Abstract][Full Text] [Related]
30. Ether lipids inhibit the effects of phorbol diester tumor promoters. Daniel LW; Etkin LA; Morrison BT; Parker J; Morris-Natschke S; Surles JR; Piantadosi C Lipids; 1987 Nov; 22(11):851-5. PubMed ID: 3444377 [TBL] [Abstract][Full Text] [Related]
31. Relationship of cell survival, drug dose, and drug uptake after 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine treatment. Fujiwara K; Daniel LW; Modest EJ; Wallen CA Cancer Chemother Pharmacol; 1994; 34(6):472-6. PubMed ID: 7923557 [TBL] [Abstract][Full Text] [Related]
32. Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Storme GA; Berdel WE; van Blitterswijk WJ; Bruyneel EA; De Bruyne GK; Mareel MM Cancer Res; 1985 Jan; 45(1):351-7. PubMed ID: 4038380 [TBL] [Abstract][Full Text] [Related]
33. Cell kill and cytostasis by ET-18-OCH3 and heat. Fujiwara K; Modest EJ; Wallen CA Anticancer Res; 1995; 15(4):1333-8. PubMed ID: 7654017 [TBL] [Abstract][Full Text] [Related]
34. The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells. Yamazaki T; Sieber F Bone Marrow Transplant; 1997 Jan; 19(2):113-9. PubMed ID: 9116607 [TBL] [Abstract][Full Text] [Related]
35. Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation. Dietzfelbinger HF; Kühn D; Zafferani M; Hanauske AR; Rastetter JW; Berdel WE Cancer Res; 1993 Aug; 53(16):3747-51. PubMed ID: 8339286 [TBL] [Abstract][Full Text] [Related]
36. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Mollinedo F; Fernández-Luna JL; Gajate C; Martín-Martín B; Benito A; Martínez-Dalmau R; Modolell M Cancer Res; 1997 Apr; 57(7):1320-8. PubMed ID: 9102220 [TBL] [Abstract][Full Text] [Related]
37. Noncytotoxic alkyl-lysophospholipid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NK) cells. Botzler C; Kolb HJ; Issels RD; Multhoff G Int J Cancer; 1996 Mar; 65(5):633-8. PubMed ID: 8598315 [TBL] [Abstract][Full Text] [Related]
38. 1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. Zhou X; Lu X; Richard C; Xiong W; Litchfield DW; Bittman R; Arthur G J Clin Invest; 1996 Aug; 98(4):937-44. PubMed ID: 8770865 [TBL] [Abstract][Full Text] [Related]
39. A comparative study of the effect of the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine and some homologous compounds on PKC alpha and PKC epsilon. Conesa-Zamora P; Mollinedo F; Corbalán-García S; Gómez-Fernández JC Biochim Biophys Acta; 2005 Feb; 1687(1-3):110-9. PubMed ID: 15708359 [TBL] [Abstract][Full Text] [Related]
40. Cytotoxic effects of ether lipids and derivatives in human nonneoplastic bone marrow cells and leukemic cells in vitro. Schick HD; Berdel WE; Fromm M; Fink U; Jehn U; Ulm K; Reichert A; Eibl H; Unger C; Rastetter J Lipids; 1987 Nov; 22(11):904-10. PubMed ID: 3444383 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]